1-[6-chloro-pyridin-3-ylmethyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-[6-chloro-pyridin-3-ylmethyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-one
• 英文别名: 1-[(6-Chloropyridin-3-yl)methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one
• 化学式: C₂₆H₂₂ClN₃O₂
• 分子量: 443.933
• InChiKey: IZEGWMCODZHPBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  54.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  {2-[(6-chloro-pyridin-3-ylmethyl)-amino]-5-propargyloxy-phenyl}-(4-isopropyl-phenyl)-methanone 、 sodium isocyanate 在 溶剂黄146 作用下， 反应 3.0h， 生成 1-[6-chloro-pyridin-3-ylmethyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-one
  参考文献：
  名称：

  [EN] DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE
  [FR] DERIVES D'ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE

  摘要：

  公开号：

  WO2004056365A3

文献信息

• Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives
  申请人：Altmann Eva

  公开号：US20060079685A1

  公开（公告）日：2006-04-13

  A compound of formula (I): wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable.

  化合物的化学式为(I): 其中R1，R2，R3和Y的定义如下，或其药学上可接受和可水解酯或酸盐，用于促进甲状旁腺激素的释放，例如预防或治疗与钙流失或吸收增加或骨形成和钙固定在骨中有关的骨病情况。
• Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone
  申请人：Novartis Pharma AG

  公开号：EP1844780A2

  公开（公告）日：2007-10-17

  A compound of formula I wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable.

  式 I 的化合物 其中 R1、R2、R3 和 Y 如本文所定义、 或其药学上可接受和可清除的酯或酸加成盐、 可用于促进甲状旁腺激素的释放，例如用于预防或治疗与钙消耗或吸收增加有关的骨病，或用于刺激骨形成和钙在骨中的固定。
• Pharmaceutical compositions comprising a calcilytic agent
  申请人：Novartis AG

  公开号：EP1964548A1

  公开（公告）日：2008-09-03

  Provided is a pharmaceutical composition comprising a calcilytic agent which, when administered orally to a subject induces a rapid and short-lasting absorption of the calcilytic agent and/or a rapid and short-lasting release of the parathyroid hormone.

  本发明提供了一种药物组合物，其中包含一种降钙剂，当口服给受试者服用时，该药物组合物能诱导降钙剂的快速、短暂吸收和/或甲状旁腺激素的快速、短暂释放。
• DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE
  申请人：Novartis AG

  公开号：EP1585521A2

  公开（公告）日：2005-10-19
• PHARMACEUTICAL COMPOSITIONS
  申请人：Buhl Thomas

  公开号：US20100022565A1

  公开（公告）日：2010-01-28

  Provided is a pharmaceutical composition comprising a calcilytic agent which, when administered orally to a subject induces a rapid and short-lasting absorption of the calcilytic agent and/or a rapid and short-lasting release of the parathyroid hormone.